- Home
- ROOT vs EYPT Comparison
ROOT vs EYPT Comparison
Compare ROOT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- EYPT
- Stock Information
- Founded
- ROOT 2015
- EYPT 1987
- Country
- ROOT United States
- EYPT United States
- Employees
- ROOT N/A
- EYPT N/A
- Industry
- ROOT Property-Casualty Insurers
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ROOT Finance
- EYPT Industrials
- Exchange
- ROOT Nasdaq
- EYPT Nasdaq
- Market Cap
- ROOT 1.2B
- EYPT 967.4M
- IPO Year
- ROOT 2020
- EYPT 2005
- Fundamental
- Price
- ROOT $81.70
- EYPT $14.72
- Analyst Decision
- ROOT Buy
- EYPT Strong Buy
- Analyst Count
- ROOT 6
- EYPT 5
- Target Price
- ROOT $125.80
- EYPT $29.60
- AVG Volume (30 Days)
- ROOT 607.1K
- EYPT 1.4M
- Earning Date
- ROOT 11-05-2025
- EYPT 11-05-2025
- Dividend Yield
- ROOT N/A
- EYPT N/A
- EPS Growth
- ROOT N/A
- EYPT N/A
- EPS
- ROOT 3.34
- EYPT N/A
- Revenue
- ROOT $1,446,800,000.00
- EYPT $42,339,000.00
- Revenue This Year
- ROOT $27.41
- EYPT N/A
- Revenue Next Year
- ROOT $9.74
- EYPT N/A
- P/E Ratio
- ROOT $24.38
- EYPT N/A
- Revenue Growth
- ROOT 38.50
- EYPT N/A
- 52 Week Low
- ROOT $68.08
- EYPT $3.91
- 52 Week High
- ROOT $181.14
- EYPT $14.96
- Technical
- Relative Strength Index (RSI)
- ROOT 51.80
- EYPT 66.37
- Support Level
- ROOT $68.08
- EYPT $13.43
- Resistance Level
- ROOT $91.00
- EYPT $14.67
- Average True Range (ATR)
- ROOT 6.17
- EYPT 0.90
- MACD
- ROOT 0.21
- EYPT 0.32
- Stochastic Oscillator
- ROOT 60.99
- EYPT 97.01
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.